Subtoxic doses of eIF2α phosphatase GADD34/PP1c inhibitors guanabenz or salubrinal reduce breast and bone cancer cell migration/invasion through the reduction of SRC [204] and RAC1 [204,205] activity and through the modulation of MMP13 expression (for salubrinal) [204]. Here, MMP13 is linked to bone neoplasm.